Clinical Trial Update: Intracranial Injection of NK-92/5.28.z Cells in Combination With Intravenous Ezabenlimab in Patients With Recurrent HER2-positive Glioblastoma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating intracranial NK-92/5.28.z cell therapy in combination with intravenous ezabenlimab for recurrent HER2-positive glioblastoma; currently …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• NK-92/5.28.z cells (NK-92/5.28.z cells)
• ezabenlimab (ezabenlimab)

Snippet

Sponsor: Johann Wolfgang Goethe University Hospital | Conditions: Glioblastoma | Phase 1 | Status: RECRUITING